中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
6期
829-831
,共3页
腹泻%双歧杆菌乳杆菌三联活菌%儿童
腹瀉%雙歧桿菌乳桿菌三聯活菌%兒童
복사%쌍기간균유간균삼련활균%인동
Diarrhea%Bifidobacterium lactobacillus triple living bacterium tablet%Child
目的 探讨双歧杆菌乳杆菌三联活菌防治小儿抗生素相关性腹泻(AAD)的临床疗效.方法 选取300例呼吸道感染患儿,首先按照年龄大小分为A组(1个月至1岁)140例,B组(＞1～3岁)160例,A、B两组内再分成观察组150例(A组:70例,B组:80例)与对照组150例(A组:70例,B组:80例).对照组应用抗生素治疗呼吸道感染,出现腹泻后给予常规治疗;观察组在应用抗生素治疗的同时给予双歧杆菌乳杆菌三联活菌片,出现腹泻后在常规治疗的基础上继续服用该药物.观察指标包括腹泻发生率、治疗总体有效率、腹泻持续时间三项.结果 A、B组中观察组与对照组腹泻发生率分别为10.0％、38.7％,观察组腹泻发生率明显低于两对照组(x2 =4.883,P＜0.05);A组中的观察组和对照组腹泻发生率分别为17.1％与40.0％,B组中分别为3.75％与37.5％,两个不同年龄组内观察组腹泻发生率明显的低于对照组(x2=4.924、5.736,均P ＜0.05);A、B两组中对照组腹泻发病率差异均统计学意义(P＞0.05);A、B两组中观察组腹泻发病率差异有统计学意义(x2=4.427,P＜0.05).观察组与对照组腹泻腹泻持续时间分别为(2.09 ±0.47)d、(5.27±1.78)d,两组差异有统计学意义(t=2.907,P＜0.05);A组中的观察组和对照组治疗腹泻持续时间分别为(2.13±0.54)d、(5.36±1.72)d,B组分别为(2.07 ±0.48)d、(5.22±1.77)d,差异有统计学意义(t=2.984、3.002,均P＜0.05).结论 双歧杆菌乳杆菌三联活菌防治小儿抗生素相关性腹泻临床疗效显著,尤其对于1～3年龄的小儿AAD预防效果更加突出,值得临床推广.
目的 探討雙歧桿菌乳桿菌三聯活菌防治小兒抗生素相關性腹瀉(AAD)的臨床療效.方法 選取300例呼吸道感染患兒,首先按照年齡大小分為A組(1箇月至1歲)140例,B組(＞1～3歲)160例,A、B兩組內再分成觀察組150例(A組:70例,B組:80例)與對照組150例(A組:70例,B組:80例).對照組應用抗生素治療呼吸道感染,齣現腹瀉後給予常規治療;觀察組在應用抗生素治療的同時給予雙歧桿菌乳桿菌三聯活菌片,齣現腹瀉後在常規治療的基礎上繼續服用該藥物.觀察指標包括腹瀉髮生率、治療總體有效率、腹瀉持續時間三項.結果 A、B組中觀察組與對照組腹瀉髮生率分彆為10.0％、38.7％,觀察組腹瀉髮生率明顯低于兩對照組(x2 =4.883,P＜0.05);A組中的觀察組和對照組腹瀉髮生率分彆為17.1％與40.0％,B組中分彆為3.75％與37.5％,兩箇不同年齡組內觀察組腹瀉髮生率明顯的低于對照組(x2=4.924、5.736,均P ＜0.05);A、B兩組中對照組腹瀉髮病率差異均統計學意義(P＞0.05);A、B兩組中觀察組腹瀉髮病率差異有統計學意義(x2=4.427,P＜0.05).觀察組與對照組腹瀉腹瀉持續時間分彆為(2.09 ±0.47)d、(5.27±1.78)d,兩組差異有統計學意義(t=2.907,P＜0.05);A組中的觀察組和對照組治療腹瀉持續時間分彆為(2.13±0.54)d、(5.36±1.72)d,B組分彆為(2.07 ±0.48)d、(5.22±1.77)d,差異有統計學意義(t=2.984、3.002,均P＜0.05).結論 雙歧桿菌乳桿菌三聯活菌防治小兒抗生素相關性腹瀉臨床療效顯著,尤其對于1～3年齡的小兒AAD預防效果更加突齣,值得臨床推廣.
목적 탐토쌍기간균유간균삼련활균방치소인항생소상관성복사(AAD)적림상료효.방법 선취300례호흡도감염환인,수선안조년령대소분위A조(1개월지1세)140례,B조(＞1～3세)160례,A、B량조내재분성관찰조150례(A조:70례,B조:80례)여대조조150례(A조:70례,B조:80례).대조조응용항생소치료호흡도감염,출현복사후급여상규치료;관찰조재응용항생소치료적동시급여쌍기간균유간균삼련활균편,출현복사후재상규치료적기출상계속복용해약물.관찰지표포괄복사발생솔、치료총체유효솔、복사지속시간삼항.결과 A、B조중관찰조여대조조복사발생솔분별위10.0％、38.7％,관찰조복사발생솔명현저우량대조조(x2 =4.883,P＜0.05);A조중적관찰조화대조조복사발생솔분별위17.1％여40.0％,B조중분별위3.75％여37.5％,량개불동년령조내관찰조복사발생솔명현적저우대조조(x2=4.924、5.736,균P ＜0.05);A、B량조중대조조복사발병솔차이균통계학의의(P＞0.05);A、B량조중관찰조복사발병솔차이유통계학의의(x2=4.427,P＜0.05).관찰조여대조조복사복사지속시간분별위(2.09 ±0.47)d、(5.27±1.78)d,량조차이유통계학의의(t=2.907,P＜0.05);A조중적관찰조화대조조치료복사지속시간분별위(2.13±0.54)d、(5.36±1.72)d,B조분별위(2.07 ±0.48)d、(5.22±1.77)d,차이유통계학의의(t=2.984、3.002,균P＜0.05).결론 쌍기간균유간균삼련활균방치소인항생소상관성복사림상료효현저,우기대우1～3년령적소인AAD예방효과경가돌출,치득림상추엄.
Objective To explore the clinical effect of bifidobacterium lactobacillus triple living bacterium tablet in the prevention and treatment of pediatric antibiotic associated diarrhea(AAD).Methods 300 children with respiratory tract infection were selected,firstly they were divided into group A(1 month-lyear old) 140 cases and group B(1-3years old) 160 cases according to the age;secondly,they were randomly divided into observation group (group A:70 cases and group B:80 cases) and control group 150 cases (group A:70 cases and group B:80 cases)within the A,B groups.Control group was given antibiotics to treat respiratory tract infection,and received conventional treatment after diarrhea appeared.Observation group was given bifidobacterium lactobacillus triple living bacterium tablet combined with antibiotics,continued to receive this drug on the basis of conventional treatment after diarrhea appeared.The incidence rate of diarrhea,total effective rate,duration of diarrhea were observed.Results The incidence rate of diarrhea of observation group was obviously lower than the control group,diarrhea treatment overall effective rate obviously higher than control group,the duration of diarrhea significantly shorter than the control group,with significant difference(P ＜ 0.05) ;The incidence rate of diarrhea of observation group in group B was obviously lower than the observation group in group A,with significant difference (P ＜ 0.05).Conclusion The clinical effect of bifidobacterium lactobacillus triple living bacterium tablet in the prevention and treatment of pediatric AAD is significant,especially for 1-3 years old children,it is worth clinical promotion.
